Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE (2016) 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. https://doi.org/10.1056/NEJMoa1606220

Article  PubMed  Google Scholar 

Fowler J, Chappell R, Ritter M (2001) Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4):1021–1031

Article  CAS  PubMed  Google Scholar 

Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101

Article  CAS  PubMed  Google Scholar 

Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17(8):1061–1069. https://doi.org/10.1016/S1470-2045(16)30070-5

Article  PubMed  Google Scholar 

Lee WR et al (2016) Randomized phase III non-inferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34(20):2325

Article  PubMed  PubMed Central  Google Scholar 

Hoffman KE et al (2014) Risk of late toxicity in men receiving dose escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88(5):1074–1084

Article  PubMed  Google Scholar 

Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnarò P, Pinzi V, Arcangeli G (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84(5):1172–1178. https://doi.org/10.1016/j.ijrobp.2012.02.049

Article  PubMed  Google Scholar 

Francolini G, Detti B, Becherini C, Caini S, Ingrosso G, Di Cataldo V, Stocchi G, Salvestrini V, Lancia A, Scartoni D, Giacomelli I, Sardaro A, Carbonara R, Borghesi S, Aristei C, Livi L (2021) Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: a systematic review and meta-analysis of the current literature. Crit Rev Oncol Hematol 165:103432. https://doi.org/10.1016/j.critrevonc.2021.103432

Article  CAS  PubMed  Google Scholar 

Nicosia L, Mazzola R, Rigo M, Figlia V, Giaj-Levra N, Napoli G, Ricchetti F, Corradini S, Ruggieri R, Alongi F (2019) Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. J Cancer Res Clin Oncol 145(10):2547–2554. https://doi.org/10.1007/s00432-019-02983-3

Article  PubMed  Google Scholar 

Franzese C, D’agostino G, Di Brina L, Navarria P, De Rose F, Comito T, Franceschini D, Mancosu P, Tomatis S, Scorsetti M (2019) Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. Br J Radiol 92(1097):20190021. https://doi.org/10.1259/bjr.20190021

Article  PubMed  PubMed Central  Google Scholar 

Foerster R, Zwahlen DR, Buchali A, Tang H, Schroeder C, Windisch P, Vu E, Akbaba S, Bostel T, Sprave T, Zamboglou C, Zilli T, Stelmes JJ, Telkhade T, Murthy V (2021) Stereotactic body radiotherapy for high-risk prostate cancer: a systematic review. Cancers (Basel) 13(4):759. https://doi.org/10.3390/cancers13040759

Article  PubMed  Google Scholar 

Osti MF, Agolli L, Valeriani M, Reverberi C, Bracci S, Marinelli L, De Sanctis V, Cortesi E, Martelli M, De Dominicis C, Minniti G, Nicosia L (2018) 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease. Lung Cancer 122:165–170. https://doi.org/10.1016/j.lungcan.2018.06.018

Article  CAS  PubMed  Google Scholar 

Alongi F, Rigo M, Figlia V, Cuccia F, Giaj-Levra N, Nicosia L, Ricchetti F, Vitale C, Sicignano G, De Simone A, Naccarato S, Ruggieri R, Mazzola R (2021) Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. Br J Radiol. 94(1117):20200848. https://doi.org/10.1259/bjr.20200848

Article  PubMed  Google Scholar 

Corradini S, Alongi F, Andratschke N et al (2019) MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol 14(1):92. https://doi.org/10.1186/s13014-019-1308-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nicosia L, Sicignano G, Rigo M, Figlia V, Cuccia F, De Simone A, Giaj-Levra N, Mazzola R, Naccarato S, Ricchetti F, Vitale C, Ruggieri R, Alongi F (2021) Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta Oncol 60(2):215–221. https://doi.org/10.1080/0284186X.2020.1821090

Article  CAS  PubMed  Google Scholar 

Ruggieri R, Rigo M, Naccarato S, Gurrera D, Figlia V, Mazzola R, Ricchetti F, Nicosia L, Giaj-Levra N, Cuccia F, Vitale C, Stavreva N, Pressyanov DS, Stavrev P, Pellegrini R, Alongi F (2020) Adaptive SBRT by 1.5 T MR-linac for prostate cancer: on the accuracy of dose delivery in view of the prolonged session time. Phys Med 80:34–41. https://doi.org/10.1016/j.ejmp.2020.09.026

Article  PubMed  Google Scholar 

Alongi F, Mazzola R, Fiorentino A, Corradini S, Aiello D, Figlia V, Gregucci F, Ballario R, Cavalleri S, Ruggieri R (2019) Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. Strahlenther Onkol 195(2):113–120. https://doi.org/10.1007/s00066-018-1338-7

Article  PubMed  Google Scholar 

Alongi F, Rigo M, Figlia V et al (2020) 1.5T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol 15(1):69

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggieri R, Naccarato S, Stavrev P et al (2015) Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. Br J Radiol 88(1054):20140736

Article  PubMed  PubMed Central  Google Scholar 

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O’Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E (2016) CHHiP investigators conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 17(8):1047–1060. https://doi.org/10.1016/S1470-2045(16)30102-4

Article  PubMed  PubMed Central  Google Scholar 

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394(10196):385–395. https://doi.org/10.1016/S0140-6736(19)31131-6

Article  PubMed  Google Scholar 

https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (online access 4 November 2022)

Gómez-Aparicio MA, Valero J, Caballero B et al (2021) 2021 Extreme Hypofractionation with SBRT in Localized Prostate Cancer. Curr Oncol. 28(4):2933–2949. https://doi.org/10.3390/curroncol28040257

Article  PubMed  PubMed Central  Google Scholar 

Meier RM, Bloch DA, Cotrutz C et al (2018) Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys 102(2):296–303. https://doi.org/10.1016/j.ijrobp.2018.05.040

Article  PubMed  Google Scholar 

Fuller DB, Falchook AD, Crabtree T et al (2018) Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes. Eur Urol Oncol 1(6):540–547. https://doi.org/10.1016/j.euo.2018.06.013

Article  PubMed  Google Scholar 

Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022 Oct;23(10):1308–1320. doi: https://doi.org/10.1016/S1470-2045(22)00517-4.

Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, Sheng K, Sharma S, Nickols NG, Pham J, Yang Y, Gao Y, Neylon J, Basehart V, Cao M, Steinberg ML (2023) Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2022.6558

Article  PubMed  PubMed Central  Google Scholar 

Kataria T, Gupta D, Goyal S, Bisht SS, Chaudhary R, Narang K et al (2016) Simple diagrammatic method to delineate male urethra in prostate cancer radiotherapy: an MRI based approach. Br J Radiol 89(1068):20160348

Article  PubMed  PubMed Central  Google Scholar 

Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P (2000) Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 89:1800–1809

Article  CAS  PubMed  Google Scholar 

De Bari B, Arcangeli S, Ciardo D, Mazzola R, Alongi F, Russi EG, Santoni R, Magrini SM, Jereczek-Fossa BA (2016) on the behalf of the Italian association of radiation oncology (AIRO). Extreme hypofractionation for early prostate cancer: biology meets technology. Cancer Treat Rev 50:48–60. https://doi.org/10.1016/j.ctrv.2016.08.005

Article  PubMed  Google Scholar